Enteroscopy Has Moved Small Bowel Disease Out of the Diagnostic Blind Spot
Evaluation of the small intestine has long posed a practical problem for gastroenterology. Its length, looping course, and relative inaccessibility make direct inspection difficult, and for many years clinicians had to rely on indirect imaging or accept incomplete answers. Device-assisted enteroscopy has changed that calculus by allowing endoscopists to reach deep segments of the small bowel, obtain tissue, and treat lesions in the same session when needed.
A narrative review published in Therapeutic Advances in Gastroenterology places enteroscopy in the center of modern small bowel care, especially when paired with capsule endoscopy and cross-sectional imaging. The review drew on a MEDLINE search covering February 2001 through February 2025 and focused on the current indications, therapeutic procedures, safety profile, and comparative role of enteroscopy in small intestine disease. The clinical message is straightforward: capsule endoscopy usually opens the case, while device-assisted enteroscopy often closes it.
Bleeding, Inflammation, Celiac Disease, and Tumors Drive Most Referrals
The strongest indications for small bowel enteroscopy remain clinically familiar: small intestinal bleeding, inflammatory bowel disease, celiac disease, and small intestine tumors. In practice, these are the patients in whom standard upper and lower endoscopy has already failed to explain anemia, overt bleeding, malabsorption, pain, diarrhea, or an abnormal imaging study.
Enteroscopy adds value because it does more than look. It can identify a bleeding source hidden beyond the reach of conventional scopes, define the extent of mucosal disease, and reveal neoplastic lesions that would otherwise stay occult. In inflammatory disorders, especially Crohn’s disease and ulcerative colitis with suspected small bowel involvement, the ability to inspect deep segments and sample abnormal mucosa helps distinguish active inflammation from complications such as strictures or ulceration. In celiac disease, enteroscopy can support evaluation when symptoms persist despite dietary treatment or when another process is suspected.
Small bowel tumors create a different kind of urgency. Even though they are less common than colorectal neoplasms, their delayed recognition often reflects the limits of routine endoscopy rather than a lack of clinical significance. Tissue diagnosis remains central, and enteroscopy provides access that capsule endoscopy cannot offer.
Capsule endoscopy usually comes first because it is noninvasive and better tolerated. That sequencing matters in everyday practice: it allows a clinician to localize abnormality before committing the patient to a technically demanding procedure. Once a lesion has been seen, device-assisted enteroscopy becomes the interventional bridge between suspicion and action.
Biopsy and Therapy Distinguish Enteroscopy From Pure Imaging
The real advantage of enteroscopy is not simply visualization. It is the ability to intervene.
When abnormalities are found, device-assisted enteroscopy permits tissue sampling and a range of therapeutic procedures in the same procedure. Hemostasis remains one of the most important uses, especially in obscure gastrointestinal bleeding where a lesion may be actively oozing or stigmata of recent hemorrhage can be treated immediately. Balloon dilation is another major application, particularly for short symptomatic benign strictures. The review identifies this as a way to reduce or defer surgery in selected patients, which is especially relevant in chronic disease where repeated operations can worsen adhesions, bowel loss, and long-term morbidity.
Polypectomy and foreign body removal also fall within the therapeutic scope of the procedure. In those settings, enteroscopy is functioning not as a diagnostic adjunct but as a definitive treatment platform. For patients with recurrent bleeding or obstructive symptoms, that distinction changes the care pathway at once.
Safety Is Acceptable, but Therapeutic Cases Carry More Risk
Enteroscopy has a reputation for technical difficulty, yet the safety data summarized in the review are reassuring. The overall complication rate for both double-balloon and single-balloon enteroscopy ranges from 0.4% to 5.5%, and no significant difference appears between the two approaches. Major adverse events, including perforation, pancreatitis, and bleeding, remain uncommon and generally do not exceed 3%.
The pattern of risk is important. Diagnostic procedures are safer than therapeutic ones, and the complication burden rises when dilation, hemostasis, or other interventions are performed. In other words, the patient most likely to benefit from therapy is also the patient who needs the most careful selection and monitoring.
Sedation is another practical issue, particularly in older adults. Elderly patients are more prone to sedation-related side effects such as aspiration and hypoxia. For a procedure that often requires prolonged examination time and deep intestinal advancement, that creates a meaningful bedside concern. It also argues for close coordination between the endoscopy team and anesthesia support in higher-risk patients.
Why Deep Access Matters in Chronic Small Bowel Disease
Enteroscopy matters because many small bowel diseases are defined by what happens beyond the reach of standard endoscopes. Bleeding lesions may be intermittent and invisible on routine studies. Inflammatory injury may be patchy, proximal, or distal. Tumors may sit quietly until anemia or obstruction forces evaluation. Small bowel strictures may be short enough to dilate yet severe enough to drive pain, vomiting, and repeated admissions. Each of these scenarios rewards direct access.
The review also makes clear that enteroscopy is not intended to replace capsule endoscopy or imaging. Instead, it fits into a stepwise diagnostic strategy. Capsule endoscopy often functions as the screening test because it is less invasive. Cross-sectional imaging may clarify anatomy, extraluminal disease, or obstruction. Enteroscopy follows when tissue confirmation or treatment is needed. That sequence is efficient, but it depends on local expertise and procedural availability.
Access and Standardization Remain the Main Constraints
Despite its value, enteroscopy remains technically demanding and is concentrated in specialized centers. Limited availability shapes real-world use as much as any procedural risk. Patients may wait longer for definitive evaluation, and smaller hospitals may depend on referral pathways that delay diagnosis or treatment.
Further standardization is needed across technique, case selection, and training. Broader access would likely increase the procedure’s impact in obscure bleeding, inflammatory bowel disease, celiac disease with unresolved symptoms, and small bowel neoplasia. For now, the procedure occupies a highly effective but still somewhat niche role: indispensable when deep small bowel access is needed, yet still dependent on the experience of the center that performs it.
The review leaves one practical message intact. When capsule endoscopy or imaging finds a lesion in the small intestine, enteroscopy is often the only route that can both confirm the diagnosis and treat it in the same sitting.